-
Grifols AS Plans to Sell Stake in Shanghai RAAS Blood Products Co., Ltd for Up to $1.5 Billion
•
Spain-based Grifols AS (NASDAQ: GRFS), a leading global player in the blood products industry, has announced its intention to sell a portion of its stake in China-based Shanghai RAAS Blood Products Co., Ltd (SHE: 002252). This strategic move is expected to yield up to USD 1.5 billion for Grifols AS,…
-
Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors
•
China-based Jiangxi Jemincare Group has announced that it has received approval from the China National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug, JYB1907, a monoclonal antibody (mAb) targeting GARP and TGF-β1, in patients with locally advanced malignant solid tumors. The drug had previously…
-
Sperogenix Therapeutics and LUCA Healthcare Join Forces to Advance Digital Therapy for Myasthenia Gravis
•
China-based rare disease specialist Sperogenix Therapeutics Limited has entered into a partnership with compatriot firm LUCA Healthcare Limited Co., a company specializing in digital targeting and healthcare solutions, to bolster the application of digital therapy in myasthenia gravis. The collaboration aims to enhance the use of digital therapy in treating…
-
NMPA Approves Suzhou MicroPort Joint Medical Technology’s Zirconium Niobium Alloy Femoral Head for Hip Replacement
•
The National Medical Products Administration (NMPA) has granted marketing approval to Suzhou MicroPort Joint Medical Technology Co., Ltd for its zirconium niobium alloy femoral head. This development marks a significant advancement in the field of orthopedic implants, offering a new option for patients undergoing total hip joint replacement surgery. Product…
-
Cytocraft Biotech’s SDT-T002 Cell Therapy Approved for Advanced Liver Cancer by NMPA
•
China-based Cytocraft Biotech Development has announced that its cell therapy, SDT-T002, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of advanced liver cancer that has failed standard treatment. Cascade Primed Immune Cells (CAPRI) Cell Therapy OverviewCytocraft boasts its Cascade Primed Immune Cells (CAPRI)…
-
Laekna Raises £791 Million in Hong Kong IPO for Pipeline Expansion
•
Sino-US Laekna (HKG: 2105) has successfully raised £791 million through an initial public offering (IPO) of 63,728,000 shares on the Hong Kong Stock Exchange, with each share priced at HKD12.41. Company Background and Core ProductsFounded in 2016, Laekna has established itself with two core products, both in-licensed from Swiss pharmaceutical…
-
Grand Pharmaceutical’s STC3141 Achieves Clinical Endpoint in Sepsis Study
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib REFINE study for its drug candidate STC3141 in sepsis has successfully reached the clinical endpoint in Australia and Belgium. Design and Results of the Phase Ib REFINE StudyThe open-label, multi-center, dosage escalation Phase Ib clinical study was…
-
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer to Drive Innovation
•
China-based Everest Medicines (HKG: 1952) has announced the appointment of Dr. Mike Berry as Chief Technology Officer, effective immediately. With over 30 years of industrial experience, Dr. Berry brings a wealth of knowledge and expertise to Everest Medicines, particularly in advancing projects from the pre-clinical development phase to commercialization. Dr.…
-
AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa
•
US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), has taken legal action against BeiGene’s (NASDAQ: BGNE) BTK inhibitor Brukinsa (zanubrutinib). The lawsuit was filed by AbbVie subsidiary Pharmacyclics in the Delaware District Court on the day it was awarded a new…
-
Janssen Submits Additional Indication Application to FDA for Carvykti in Multiple Myeloma
•
The Janssen subsidiary of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an additional indication application to the US Food and Drug Administration (FDA) for its CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel). The application seeks approval for the treatment of relapsed or refractory multiple myeloma (r/rMM) in adults who have…
-
Dartsbio Pharmaceuticals and SIMM Receive NMPA Approval for ADC DS001 Clinical Trial
•
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has partnered with the Shanghai Institute of Materia Medica (SIMM) to receive tacit clinical trial approval from the National Medical Products Administration (NMPA) for their antibody drug conjugate (ADC), DS001. The molecule is set to be assessed as a potential treatment for various advanced…
-
Hubei Guangji Pharmaceutical Partners with Jiangnan University for Green Manufacturing Innovation Lab
•
China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) has announced a strategic partnership with Jiangnan University to establish a joint innovation laboratory. The focus of this collaboration will be on advancing the key technologies of green manufacturing and biosynthesis of functional polysaccharides and functional proteins, including human milk oligosaccharides. Leveraging…
-
Hybio Pharmaceutical’s Semaglutide API Receives FDA Review Acceptance
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the US Food and Drug Administration (FDA) has accepted for review the market filing for its semaglutide active pharmaceutical ingredients (APIs). This development marks a significant step for the company as it seeks to enter the global market with its…
-
YSB Inc. Lists on HKSE with HKD 363.6 Million IPO, Targeting Digital Pharma Services
•
China-based ex-hospital digital pharmaceutical service platform YSB Inc. (HKG: 9885) has successfully made its initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company issued 15,808,800 shares, priced at HKD23 per share, resulting in a total capital raise of HKD 363.6 million. Shanghai Fosun Pharmaceutical Group Co.,…
-
Mabwell Bioscience’s IL-11 mAb 9MW3811 Receives US FDA Clinical Trial Approval
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its drug candidate, 9MW3811. This molecule is an in-house developed IL-11 monoclonal antibody (mAb) intended for the treatment of idiopathic pulmonary fibrosis (IPF). Therapeutic…
-
Hansoh Pharmaceutical Gets NMPA Approval for HIF-2α Inhibitor HS-10516 Clinical Study
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its Category 1 candidate drug, HS-10516. The trial will evaluate the small-molecule hypoxia-inducible factor 2α (HIF-2α) inhibitor as a potential treatment…
-
Sino Biopharmaceutical Secures Exclusive Rights to Gmax Biopharm’s GMA106 in Greater China
•
Sino Biopharmaceutical Ltd (HKG: 1177) through its subsidiary Chia Tai Tianqing Pharmaceutical Co., Ltd, has entered into a licensing agreement with Gmax Biopharm, securing exclusive development and commercialization rights in Greater China for Gmax’s GMA106. The agreement involves Sino Bio paying Gmax Bio a combined USD 57 million in upfront…
-
UIH Surgical to Invest RMB 2.5 Billion in Wuhan Medical Innovation and Robotics Base
•
United Imaging Healthcare Technology Co., Ltd (UIH), through its subsidiary UIH Surgical, has announced plans to invest RMB 2.5 billion (USD 349.2 million) in the establishment of a medical innovation base in Wuhan Optics Valley. The project will also include the development of an intelligent production base for medical robots,…
-
JJET’s IPO on STAR Market Accepted, Aims to Raise RMB 2.691 Billion for Medical Device Expansion
•
China-based JJET has received acceptance for its Initial Public Offering (IPO) filing on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The offering is anticipated to raise RMB 2.691 billion (USD 375.9 million), with the proceeds earmarked for the construction of the company’s medical device research and development and technology…
